Education
About Us
Working with TipRanks
Follow Us
Tenax Therapeutics (TENX)
NASDAQ:TENX
TENX Stock Chart & Stats
$7.23
<$0.01(0.16%)
At close: 4:00 PM EST
$7.23
<$0.01(0.16%)
Day’s Range― - ―
52-Week Range$4.04 - $8.24
Previous CloseN/A
Volume25.45K
Average Volume (3M)120.73K
Market Cap
$32.99M
Enterprise Value$122.47M
Total Cash (Recent Filing)$105.46M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Nov 12, 2025EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding4,562,500
10 Day Avg. Volume101,465
30 Day Avg. Volume120,727
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap3.71
Enterprise Value/Revenue61.24K
Enterprise Value/Gross Profit122.47K
Enterprise Value/Ebitda-3.89
Forecast
1Y Price Target
$17.00Price Target Upside135.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Financial StabilityTENX has reported $105.5 million in cash and cash equivalents, providing a cash runway through 2027.
Market PotentialEurope is a significant market with approximately equivalent PH-HFpEF prevalence as the U.S., and Tenax has filed for patent protection in additional geographies.
Patent ProtectionThe European Patent Office plans to grant patent protection in Europe for the use of levosimendan in pulmonary hypertension resulting from heart failure with preserved ejection fraction, enhancing Tenax's market position.
Bears Say
Clinical Trial DelaysThe timeline for the Ph3 LEVEL Study in PH-HFpEF has been delayed, with topline data now expected in the second half of 2026.
Enrollment ChallengesEnrollment in the Phase III LEVEL study of oral levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction is now expected to complete in the first half of 2026.
Increased ExpensesR&D and SG&A expenses for the quarter were higher than expected, totaling $6 million each.
Tenax Therapeutics News
TENX FAQ
What was Tenax Therapeutics’s price range in the past 12 months?
Tenax Therapeutics lowest stock price was $4.04 and its highest was $8.24 in the past 12 months.
What is Tenax Therapeutics’s market cap?
Tenax Therapeutics’s market cap is $32.99M.
When is Tenax Therapeutics’s upcoming earnings report date?
Tenax Therapeutics’s upcoming earnings report date is Nov 12, 2025 which is in 13 days.
How were Tenax Therapeutics’s earnings last quarter?
Tenax Therapeutics released its earnings results on Aug 13, 2025. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.266 by -$0.004.
Is Tenax Therapeutics overvalued?
According to Wall Street analysts Tenax Therapeutics’s price is currently Undervalued.
Does Tenax Therapeutics pay dividends?
Tenax Therapeutics does not currently pay dividends.
What is Tenax Therapeutics’s EPS estimate?
Tenax Therapeutics’s EPS estimate is -0.31.
How many shares outstanding does Tenax Therapeutics have?
Tenax Therapeutics has 4,562,500 shares outstanding.
What happened to Tenax Therapeutics’s price movement after its last earnings report?
Tenax Therapeutics reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.266. Following the earnings report the stock price went up 0.677%.
Which hedge fund is a major shareholder of Tenax Therapeutics?
Currently, no hedge funds are holding shares in TENX
Tenax Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.00 (135.13% Upside)
$17.00 (135.13% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 7.3%
Last 30 Days ▲ 7.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
71.41%
12-Months-Change
Fundamentals
Return on Equity
-56.12%
Trailing 12-Months
Asset Growth
897.06%
Trailing 12-Months
Company Description
Tenax Therapeutics
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
TENX Stock 12 Month Forecast
Average Price Target
$17.00
▲(135.13% Upside)
Technical Analysis
Tempest Therapeutics
―
Relmada Therapeutics
―
VYNE Therapeutics
―
Longeveron
―
Calidi Biotherapeutics
―
Ownership Overview
0.21%
Insiders
1.42% Mutual Funds
<0.01% Other Institutional Investors
95.19% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---